Dartmouth-Hitchcock logo
Medicine Grand Rounds - Idiopathic Pulmonary Fibrosis: Recent Advances and Future Directions

Dr. Lederer presents a well-structured guide to help analyze the complex pathobiology associated with this enigmatic disease. He describes a healthy state of lung function as compared with clinical and structural changes in alveolar fibrosis and offers several categories of causes for the development alveolar injury. He emphasizes the clinical exam, especially looking at the hands, lung sounds, spirometry, high resolution CT scans and serology when an IPF diagnosis is suspected. Dr. Lederer discusses two medications that are approved for treating IPF as well as promising therapies that may improve functional health and clinical outcomes for these patients with prognostic uncertainty.

Activity Details

Start Date: February 1, 2019
End Date: February 1, 2021

You may claim CME credit for successful completion of this online course. In order to claim credit, you must follow these steps:

  1. Register for the learning activity by creating an account or logging in to your account.
  2. Click Continue to navigate to the Activity Material tab. Click View Presentation to view the recording.
  3. Return to this Activity page.
  4. Click Continue to navigate to the Evaluation tab; then click the Launch button to start the evaluation.
  5. Complete and Submit the evaluation and attestation form.

When the evaluation is submitted, you will be awarded credit. You may access your transcript for verification of participation at any time via Your Account. Need help? Visit the Support Page, send an Email, or call the Center for Learning and Professional Development at (603) 653-1234, Option 1.

  • David J. Lederer, MD, MS
    Associate Professor of Medicine and Epidemiology 
    Founder, Pulmonary and Intensive Care Translational Outcomes Research Group
    Columbia University Irving Medical Center
        Co-Director, Interstitial Lung Disease Program
        New York Presbyterian Hospital
    Dr. David J. Lederer is a graduate of SUNY Downstate College of Medicine and earned an MS in Biostatistics and Patient Oriented Research from the Columbia University Mailman School of Public Health. He completed his internal medicine residency, chief residency, and fellowship in pulmonary and critical care medicine at Columbia University Medical Center. He is the principal investigator of the NIH-funded MESA Lung Fibrosis and ACT-IPF studies. Dr. Lederer is Editor-in-Chief of the Annals of the American Thoracic Society, and is a Senior Medical Advisor for the Pulmonary Fibrosis Foundation.
Learning Outcome

At the conclusion of this activity, participants will be able to implement new diagnostic approaches to Idiopathic Pulmonary Fibrosis (IPF)  in clinical practice, discuss efficacy and safety of FDA-approved therapies for IPF, and describe biological pathways underlying IPF that are being targeted by pipeline therapies.


Dartmouth-Hitchcock is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Dartmouth-Hitchcock designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Requirements for Successful Completion

In order to receive credit for this Continuing Medical Education (CME) activity, you must:

  • View the entire presentation
  • Complete the online Attestation of Attendance & Evaluation Form (you must register to access).

In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.

The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for Idiopathic Pulmonary Fibrosis: Recent Advances and Future Directions (Medicine Grand Rounds) have reported the following financial interest or relationship* with various companies/organizations. The Activity Director and Planning Committee member roles were resolved by altering the individual’s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. The speaker's conflicts have been resolved by validating the activity content through independent peer review by Kelly Kieffer, MD. All potential conflict(s) were resolved.

* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio. 

* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and has other financial interest from Allurion.

*  David J. Lederer, MD ~ reported grant/research support from Boehringer-Ingelheim; Fibrogen; and Global Blood Therapeutic. He is a consultant with Roche; Veracyte and Galapagos.

Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.

*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.

Provider Contact Information

Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
Dartmouth-Hitchcock Medical Center

Type:     Internet Activity (Enduring Material)
16 Registered Users